RNA Phage VLP-Based Vaccine Platforms

David S Peabody; Julianne Peabody; Steven B Bradfute; Bryce Chackerian

doi:10.3390/ph14080764

RNA Phage VLP-Based Vaccine Platforms

Pharmaceuticals (Basel). 2021 Aug 4;14(8):764. doi: 10.3390/ph14080764.

Authors

David S Peabody¹, Julianne Peabody¹, Steven B Bradfute², Bryce Chackerian¹

Affiliations

¹ Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
² Center for Global Health, Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 505, USA.

Abstract

Virus-like particles from a variety of RNA bacteriophages have turned out to be useful platforms for delivery of vaccine antigens in a highly immunogenic format. Here we update the current state of development of RNA phage VLPs as platforms for presentation of diverse antigens by genetic, enzymatic, and chemical display methods.

Keywords: RNA bacteriophage; VLP; vaccines; virus-like particle.

Publication types

Review

Abstract

Publication types

Grants and funding